– Launches Pabal to tame postpartum haemorrhage
The pursuit and implementation of strategies that will aid the reduction of maternal mortality in Nigeria, in tandem with the Sustainable Development Goals (SDGs), is the driving philosophy of Ferring Pharmaceuticals, says Pharm. Yemi Aladeniyi, the company’s country manager.
Speaking with Pharmanews in an exclusive interview at the launch of Pabal (Carbetocin), a medication for the treatment of postpartum haemorrhage at Sheraton Hotel, Ikeja, Lagos, recently, Aladeniyi said that while Nigeria had the highest maternal mortality rate in the world, it had also been confirmed that postpartum haemorrage was the highest cause of maternal mortality.
He noted that to reduce the incidence of maternal mortality, physicians must be able to get all necessary tools to tackle postpartum haemorrhage, adding that Pabal had been introduced as one of the superior products to join others to combat postpartum haemorrahage and maternal mortality.
Pabal, the Ferring boss said, is a novel product that would be of great benefit to medical practice in Nigeria, noting that studies had shown that Pabal would be quite invaluable in the country, considering its power supply challenges, as the medication is temperature stable.
“The advantage of this is that because Pabal is room-temperature stable, it can be easily transported and used, while oxytocin has to be refrigerated and cold chain for it during transportation has to be rigorously ensured,” Aladeniyi said.
The Ferring boss stated further that Pabal (Carbetocin), compared to oxytocin, had also been shown in studies not to need additional uterotonics and also more effective than a continuous infusion of oxytocin. Pabal, he said, is therefore better than oxytocin because it is convenient to use, easy to administer and caregivers spend less time monitoring patients while using it.
Aladeniyi also disclosed that Ferring, WHO and another organisation had jointly conducted a research, using Pabal, adding that the research, tagged “champion study” was done in 12 countries, which included Nigeria.
He said that the purpose of the research was to ascertain the heat stability of Pabal, disclosing further that based on the confirmation of Pabal’s heat stability by the study, WHO is interested in making the product available in low resource settings like Nigeria as first line drug for prevention and treatment of postpartum haemorrhage.
Discussions, he said, were ongoing to make funding available so that the product couls be made available to end-users at considerably affordable price.
Dignitaries at the official launch included Professor Oluwarotimi Akinola, president, Society of Gynaecology & Obstetrics of Nigeria (SOGON); Professor Bukola Fawole from the department of Obstetrics & Gynaecology, College of Medicine/University College Hospital; Ibadan and Sir Sabaratnam Arulkumaran, emeritus professor of obstetrics and gynaecology from St. George University of London, United Kingdom.
The highlight of the occasion was the unveiling of Pabal by dignitaries at the event.